Vial Announces Dosing of First Patient in Phase 1 Healthy Volunteer Trial
Vial Logo

Updates

Search
All Resources
Press Releases
Videos

Obesity expert and researcher, Dr. Lawrence Cheskin MD, discusses how targeting adipose tissue is critical for treating obesity, positioning INHBE siRNA as a promising target to drive quality fat loss.

Dr. Scott Kahan, Director of the National Center for Weight and Wellness at Johns Hopkins Bloomberg School of Public Health, highlights the importance of new mechanisms of action beyond GLP-1 therapies.

Dr. Lee Kaplan, Director at Dartmouth Health’s Weight and Wellness Center, points to the myostatin/activin pathway as a promising target.

Dr. Jens Juul Holst, Professor at the Department of Biomedical Sciences and Senior Group Leader at Novo Nordisk Foundation Center for Basic Metabolic Research on the next breakthroughs in obesity treatment.

Vial’s INHBE siRNA is designed to block Activin E signaling and increase lipolysis for fat-selective weight loss selective fat reduction and muscle preservation is a profile with meaningful clinical potential. Dr. Massimo Volpe, Professor of Cardiology at the University of Rome Sapienza, shares his perspective on why this approach could transform patient care.

Dr. Jason Fung: Treating obesity means more than weight loss – it’s about correcting metabolic disease. Vial’s INHBE siRNA can help obese and overweight populations avoid major health issues.

Vial Initiates Phase 1 Trial of VIAL-INHBE, an INHBE (Activin E) siRNA for the Treatment of Obesity

Read Article

Could the next generation of obesity treatments help preserve muscle and enhance fat loss? Dr. Tim Garvey (UAB) shares how INHBE inhibition could complement GLP-1 therapies for broader benefit.

Dr. Arya M. Sharma, MD, DSc (hon), FRCPC, FCAHS, Emeritus Professor of Medicine at the University of Alberta, highlights INHBE as a promising new target for obesity, acting on both adipocytes and hepatocytes to drive fat-selective weight loss.

Load More

Obesity expert and researcher, Dr. Lawrence Cheskin MD, discusses how targeting adipose tissue is critical for treating obesity, positioning INHBE siRNA as a promising target to drive quality fat loss.

Dr. Scott Kahan, Director of the National Center for Weight and Wellness at Johns Hopkins Bloomberg School of Public Health, highlights the importance of new mechanisms of action beyond GLP-1 therapies.

Dr. Lee Kaplan, Director at Dartmouth Health’s Weight and Wellness Center, points to the myostatin/activin pathway as a promising target.

Dr. Jens Juul Holst, Professor at the Department of Biomedical Sciences and Senior Group Leader at Novo Nordisk Foundation Center for Basic Metabolic Research on the next breakthroughs in obesity treatment.

Vial’s INHBE siRNA is designed to block Activin E signaling and increase lipolysis for fat-selective weight loss selective fat reduction and muscle preservation is a profile with meaningful clinical potential. Dr. Massimo Volpe, Professor of Cardiology at the University of Rome Sapienza, shares his perspective on why this approach could transform patient care.

Dr. Jason Fung: Treating obesity means more than weight loss – it’s about correcting metabolic disease. Vial’s INHBE siRNA can help obese and overweight populations avoid major health issues.

Vial Initiates Phase 1 Trial of VIAL-INHBE, an INHBE (Activin E) siRNA for the Treatment of Obesity

Read Article

Could the next generation of obesity treatments help preserve muscle and enhance fat loss? Dr. Tim Garvey (UAB) shares how INHBE inhibition could complement GLP-1 therapies for broader benefit.

Dr. Arya M. Sharma, MD, DSc (hon), FRCPC, FCAHS, Emeritus Professor of Medicine at the University of Alberta, highlights INHBE as a promising new target for obesity, acting on both adipocytes and hepatocytes to drive fat-selective weight loss.